Cargando…

P15-23. Community engagement strategies in the Canadian HIV vaccine initiative

Detalles Bibliográficos
Autores principales:	Milsom, P, Cryan, C, Sternthal, S, Harmston, C
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767720/ http://dx.doi.org/10.1186/1742-4690-6-S3-P224

Ejemplares similares

P15-20. Developing a national policy agenda for the Canadian HIV vaccine initiative
por: Sarazin, V, et al.
Publicado: (2009)

P15-22. Potential synergies between HIV vaccines, microbicides and pre-exposure prophylaxis
por: Sarazin, V, et al.
Publicado: (2009)

P15-15. Advocates' perspectives on community engagement in the HVTN 505
por: Warren, M, et al.
Publicado: (2009)

P15-19. Evaluating community engagement efforts in a large, multi-site, global HIV vaccine trials network
por: Maggard, K, et al.
Publicado: (2009)

P15-27. Community involvement and ethics in HIV vaccine trial in Nigeria
por: Adeyemi, AO, et al.
Publicado: (2009)

P15-17. Social media as a tool for engaging and educating audiences around HIV vaccine research and clinical trial participation
por: Sitar, S, et al.
Publicado: (2009)

P15-11. Preventive HIV vaccine acceptability: a systematic review and meta-analysis
por: Newman, PA, et al.
Publicado: (2009)

P15-18. Behavioral and social science in HIV vaccine clinical research: workshop recommendations
por: Lau, C, et al.
Publicado: (2009)

P15-25. Preparation for HIV vaccine trials in Africa: barriers and facilitators for the establishment of a community advisory board in Burkina Faso
por: Berthe, A, et al.
Publicado: (2009)

Identifying practices and strategies to increase HIV testing among Haitian migrant communities
por: Santiago, Jonathan, et al.
Publicado: (2010)

P15-26. Leveraging motivators to participation in HIV vaccine research in the age of Obama
por: Alexander, SB, et al.
Publicado: (2009)

Wegener granulomatosis: type of presentation and initial treatment in a series of 23 cases
por: Martínez-Pérez, Rosalia, et al.
Publicado: (2012)

P15-03. HIV vaccine funding trends entering a global recession: research and development (R&D) from 2000 – 2008
por: Fisher, K, et al.
Publicado: (2009)

P15-28. Attitudes and awareness of HIV vaccine research in HIV uninfected MSM in four US cities: Rochester, Boston, San Francisco and Philadelphia
por: Alexander, SB, et al.
Publicado: (2009)

Integral HIV-STI diagnosis at the first VCT visit as strategy to prevent late ART initiation in the HIV-AIDS program of Mexico City (HIVPMC)
por: Juárez-Figueroa, L, et al.
Publicado: (2012)

P15-01. Willingness to participate in actual preventive HIV vaccine phase I/IIa trial in Bangkok, Thailand
por: Hemachandra, A, et al.
Publicado: (2009)

Multivalent adenoviral vectors which use an antigen capsid-incorporation strategy for HIV vaccination
por: Gu, L, et al.
Publicado: (2012)

P16-23. Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance
por: Tenzer, S, et al.
Publicado: (2009)

P15-14. Assuring data quality of the phase III vaccine trial of ALVAC vaccine priming and AIDSVAX vaccine boosting in Thailand
por: Kaewkungwal, J, et al.
Publicado: (2009)

Willingness to participate in HIV vaccine efficacy trials in a population of fishing communities, Uganda
por: Nanvubya, A, et al.
Publicado: (2012)

Adherence to HIV treatment guidelines for initiation of antiretroviral therapy in Australia
por: Bloch, M, et al.
Publicado: (2010)

Effect of 23-valent pneumococcal polysaccharide vaccine on medical expenses in Japan
por: Satomura, Kazunari, et al.
Publicado: (2014)

P15-12. Community advisory boards' successes and challenges in AIDS vaccine clinical trials: a Southern Africa experience
por: Mokhele, T
Publicado: (2009)

P14-11. Educating community medical providers about HIV vaccine induced seropositivity
por: Mark, KE, et al.
Publicado: (2009)

P19-39. Vaccibodies: a novel vaccine strategy for HIV that target viral antigens to APC
por: Øynebråten, I, et al.
Publicado: (2009)

HIV activates indoleamine 2,3-dioxygenease: inhibition of T cell proliferation by tryptophan starvation
por: Boasso, A, et al.
Publicado: (2006)

Initial Brazilian experience of Telestroke for thrombolysis in a community hospital
por: Abreu Filho, CA, et al.
Publicado: (2013)

HIV patients admitted to an ICU of a university hospital - experience of 15 years: 1995 to 2009
por: Agrifoglio, A, et al.
Publicado: (2013)

P15-05. Evaluation and recommendations on good clinical laboratory practice (GCLP) guidelines for phase I-III HIV vaccine clinical trials
por: Sarzotti-Kelsoe, M, et al.
Publicado: (2009)

P15-09. The potential global market size and public health value of hypothetical HIV-1 preventive vaccines with different levels of efficacy
por: Marzetta, CA, et al.
Publicado: (2009)

P15-30 LB. An evaluation of prescreen recruitment data: enrolling racial/ethnic minorities in Phase I HIV vaccine clinical trials
por: Johnson, D, et al.
Publicado: (2009)

Hypothermia and recovery from respiratory arrest in a neonatal rat in-vitro brainstem preparation
por: Feldman, JL, et al.
Publicado: (2001)

P12-15. Replication enhancement of an alphaviral-lentiviral replicating chimeric particle (RCP) vaccine
por: Young, K, et al.
Publicado: (2009)

P15-06. Brighton collaboration viral vector vaccines safety working group (V3SWG): maximizing the comparability and value of safety data from HIV vaccine trials
por: Chen, RT, et al.
Publicado: (2009)

Initial anticoagulation strategy for extracorporeal cardiopulmonary resuscitation patients
por: Iwashita, Y, et al.
Publicado: (2014)

Liver transplantation in the critically ill: a Canadian collaboration
por: Karvellas, C, et al.
Publicado: (2012)

P09-15. Selection of higher avidity HLA-restricted T cell responses as a viral adaptation strategy
por: Keane, N, et al.
Publicado: (2009)

Using the media social Facebook to increase the community voluntarism and engagement to monitoring ARV in Indonesia
por: Widjaja, Irwandy, et al.
Publicado: (2014)

P14-09. Use of HIV rapid tests for assessment of persistence of vaccine induced antibodies among HIV vaccine recipients
por: Karita, E, et al.
Publicado: (2009)

P14-15 LB. The safety and immunogenicity of HIV-1 vaccines based on DNA and replication competent vaccinia vector in phase I clinical trial
por: Shao, Y, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_6t5soe11vbnddbd84okt0vkatb